BillionToOne, Inc.
BLLNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, BillionToOne, Inc. (BLLN) is listed under Diagnostics & Research. With a market capitalization of $4.67B, it sits in mid-cap territory. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Market Cap
$4.67B
Beta
—
P/E (TTM)
137.58
P/E (Fwd)
66.71
EPS (TTM)
$0.72
EPS (Fwd)
$1.49
ROE
10.7%
ROA
5.2%
Cash
$548.6M
Total Debt
$143.9M
Free CF
$12.0M
52W Change
-8.8%
Annual Financials
Cash vs Debt
Where BLLN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, BLLN finished 2.15% below its 150-day moving average ($94.35) and 2.95% below its 200-day moving average ($95.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLLN overbought or oversold?
At the September 2, 2026 close, BLLN's RSI(14) was 42.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $548.6M in cash comfortably exceeding the $143.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $12.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 10.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base.
With cash comfortably exceeding debt, BLLN has financial flexibility that may help navigate uncertain periods. At over 50x earnings, BLLN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing BLLN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.